Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion

  • Name:

    Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion

  • Company:
    info
  • Active Ingredients:

    levobupivacaine hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 24/09/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 24/7/2019

Click on this link to Download PDF directly

AbbVie Limited

AbbVie Limited

Company Products

Medicine NameActive Ingredients
Medicine Name Chirocaine 1.25mg/ml solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Chirocaine 2.5 mg/ml solution for injection/concentrate for solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Chirocaine 7.5 mg/ml solution for injection/concentrate for solution for infusion Active Ingredients levobupivacaine hydrochloride
Medicine Name Duodopa intestinal gel Active Ingredients Carbidopa Monohydrate, Levodopa
Medicine Name Forane 99.9% w/w, inhalation vapour liquid Active Ingredients Isoflurane
Medicine Name Moderiba 200mg Film-coated Tablets Active Ingredients Ribavirin
Medicine Name Moderiba 400mg Film-coated Tablets Active Ingredients Ribavirin
Medicine Name Moderiba 600mg Film-coated Tablets Active Ingredients Ribavirin
Medicine Name Sevorane Active Ingredients Sevoflurane
Medicine Name Zemplar 1 microgram capsules, soft Active Ingredients Paricalcitol
Medicine Name Zemplar 2 micrograms capsules, soft Active Ingredients Paricalcitol
Medicine Name Zemplar 5 microgram/ml Solution for Injection Active Ingredients Paricalcitol
1 - 0 of 13 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 24 September 2019 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 24 July 2019 PIL

Reasons for updating

  • Change to section 2 - excipient warnings

Updated on 24 July 2019 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 18 July 2018 SmPC

Reasons for updating

  • File format updated to PDF

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 9 July 2018 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Description of change

 

SmPC was updated to reflect approval of Type IB Label alignment for Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion.

 

The following is summary of the changes:

 

The Summary of Product Characteristics title has been added in line with QRD

 

4.1     Therapeutic indications

Minor editorial updates.

 

4.2     Posology and method of administration

Minor editorial updates

 

4.3     Contraindications

Minor editorial update

 

4.4     Special warnings and precautions for use

Minor editorial updates.

 

4.5     Interaction with other medicinal products and other forms of interaction

Minor editorial updates.

 

4.6     Fertility, pregnancy and lactation

Minor editorial update.

 

4.8     Undesirable effects

Minor editorial updates.

 

10.       Date of Revision of Text

Update to July 2018.

Updated on 16 November 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 16 November 2016 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 4 April 2016 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 25 January 2016 SmPC

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change to MA holder contact details

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7: Marketing Holder Authorisation:

Update to MAH address

Updated on 25 January 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 25 January 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 7 August 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 22 June 2015 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 22 June 2015 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

To update Section 4.4 of the SmPC to include adverse drug reaction of chondrolysis in patients receiving post-operative intra-articular continuous infusion of local anaesthetics.

Updated on 19 February 2015 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 & Section 4.2

No data are available in paediatric population < 6 months of age.

 

 

Section 4.8

Information on how to report an AE in Ireland.

Updated on 18 February 2015 PIL

Reasons for updating

  • Change to improve clarity and readability

Updated on 11 July 2013 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 10 July 2013 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Marketing Authorisation holder changed from

Abbott Laboratories Ireland Ltd

4051 Kingswood Drive

Citywest Business Campus

Dublin 24



to

AbbVie Limited

Block B

Liffey Valley Office Campus

Quarryvale

Co.Dublin


Section 8

PA number changed from 
PA 38/71/7 to PA 1824/3/2

Updated on 5 June 2013 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.2 (Posology and method of administration)
The following statement has been added:

There is limited safety experience with levobupivacaine therapy for periods exceeding 24 hours. In order to minimise the risk for severe neurological complications, the patient and the duration of administration of levbupivacaine should be closely monitored (see Section 4.4).

Section 4.4 (Special warnings and precautions for use)
The following sub section has been added:

Epidural Analgesia

There have been postmarketing reports of cauda equina syndrome and events indicative of neurotoxicity (see Section 4.8) temporally associated with the use of levobupivacaine for 24 hours or more for epidural analgesia. These events were more severe and in some cases led to permanent sequelae when levobupivacaine was administered for more than 24 hours. Therefore,  infusion of levobupivacaine for a period exceeding 24 hours should be considered carefully and only be used when benefit to the patient outweighs the risk.

It is essential that aspiration for blood or cerebrospinal fluid (where applicable) be done prior to injecting any local anesthetic, both before the original dose and all subsequent doses, to avoid intravascular or intrathecal injection. However, a negative aspiration does not ensure against intravascular or intrathecal injection. Levobupivacaine should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics, since the toxic effects of these drugs are additive.

Section 4.8

The paragraph:

Rare reports have been received of cauda equina syndrome or signs and symptoms of potential injury to the base of the spinal cord or spinal nerve roots (including lower extremity weakness or paralysis, loss of bowel control and/or bladder control and priapism) associated with bupivacaine or levobupivacaine therapy.

has been changed to:

Reports have been received of cauda equina syndrome or signs and symptoms of potential injury to the base of the spinal cord or spinal nerve roots (including lower extremity
paraesthesia,
weakness or paralysis, loss of bowel control and/or bladder control and priapism) associated with levobupivacaine administration. These events were more severe and in some cases did not resolve when levobupivacaine was administered for more than 24 hours (see Section 4.4).

The sentence:

"There have been rare reports of transient Horner's syndrome---" has been changed to "There have been reports of transient Horner's syndrome---"

Updated on 6 February 2013 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

New individual SPC for Chirocaine 5 mg/ml solution for injection/concentrate for solution for infusion.  The following update has been made to section 4.2 of the SPC:

The following statement has been added under "Children".
The maximum dosage should be adjusted according to the size, body constitution and physical status of the patient/child.


Update has been made to the dosing table to better clarify the volume of the product for the 2.5 mg/ml concentration required to administer a dose of 1.25 mg/kg/side and the volume of the product for the 5.0 mg/ml concentration required to administer a dose of 1.25 mg/kg/side

Updated on 1 February 2013 PIL

Reasons for updating

  • Correction of spelling/typing errors

Updated on 11 December 2012 PIL

Reasons for updating

  • Change to marketing authorisation holder

Updated on 11 December 2012 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 16 November 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 4 November 2010 PIL

Reasons for updating

  • Change to side-effects

Updated on 22 June 2010 PIL

Reasons for updating

  • Change to MA holder contact details

Updated on 7 October 2009 PIL

Reasons for updating

  • Change to warnings or special precautions for use

Updated on 26 June 2009 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 17 February 2009 PIL

Reasons for updating

  • New PIL for medicines.ie